Fig. 3.

Zoledronic acid weakens the stemness phenotypic characteristics of cervical cancer cells derived CSCs. Approximately 50 and 100 cells derived from cervical cancer cells derived CSCs were seeded in 24-well plates and treated with 10, 20, and 30 μM zoledronic acid. The colonies (> 50 cells) were counted under the microscope. The histograms show the SFE of cervical cancer cells derived CSCs treated with 10, 20, and 30 μM zoledronic acid (a). Representative morphology difference of HeLa cells derived CSCs treated or not with zoledronic acid (10, 20, and 30 μM), original magnification, × 400 (b). Western blot analysis of ALDH1, Sox2, CD49f, Nanog, and Oct4 in cervical cancer cells derived CSCs treated or not with zoledronic acid (10, 20, and 30 μM) (c). The migrated HeLa cells derived CSCs after being treated or not with 10, 20, and 30 μM zoledronic acid, respectively; original magnification, × 200 (d). The histograms show the migrated number of cervical cancer cells derived CSCs (e). Western blot analysis of E-cadherin, N-cadherin, and Vimentin in cervical cancer cells derived CSCs treated or not with zoledronic acid (10, 20, and 30 μM) (f). Control vs. 10, 20, and 30 μM zoledronic acid: * P < 0.05, ** P < 0.01. Results are shown as mean values ± SD of independent experiments performed in triplicate